M Ventures
€600m
Fund allocation
2009
Inception of M Ventures
100+
Total investments
Entrepreneurs at heart in Biotechnology and Technology
M Ventures is the strategic, corporate venture capital fund of Merck KGaA, Darmstadt, Germany, investing in Biotechnology and Technology. We cover the areas of Healthcare drug development, Life Science tools, Electronics and Frontier Technology & Sustainability.
We invest - with dual strategic and financial foci - into visionary companies that find new ways to: treat the most challenging diseases, empower scientists with cutting-edge research and development tools, develop new solutions that change the way in which information is accessed, stored, processed, and displayed and address some of the most complex challenges in sustainability and technology convergence.
We take an active role in our portfolio companies and team up with entrepreneurs and co-investors to translate innovation towards commercial success.
“They never stop asking the hard questions—the kind worth answering to advance our innovation.”
ImmuneBridge is amplifying nature's innate intelligence to develop allogeneic immunotherapies for cancer.
“They add significant business value on a monthly basis and have proven to be very founder friendly.”
Tignis combines the precise insights of physics with the most advanced AI and ML data science to give semiconductor equipment manufacturers, wafer fabs, and components and materials suppliers unprecedented automation and process control.
“MV investment provides scientific and business insights relevant to a startup.”
Outrun Therapeutics is an E3 ligase inhibitor company leveraging its activity-based probe as a platform to discover and develop novel therapeutics for cancer and other relevant diseases.
“MV investment is very practical and collaborative, always putting the best interests of the company at the forefront. Furthermore, they are always available and willing to help.”
MemryX is a fabless semiconductor company that designs and sells innovative Edge AI processors
“M Ventures has been the guardian angel of Calypso Biotech since its birth!”
Calypso Biotech is an immunotherapy biotech company, spin-off from Merck KGaA, Darmstadt, Germany, that discovers and develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs.
“With their commitment to our project, fundraising during seed and series A investment rounds became much easier.”
Solving the holy grail of OLED research: an efficient AND stable, deep-blue emitter for next gen OLED displays
“Hands on when they need to be. Hands off when they need to be. Always supportive. That’s M Ventures!”
At Neurable, we’re translating brain activity into simple, actionable insights you can use in your everyday life. After all, your brain knows you best.
“Unfortunately there is no quote by Rob Devlin. Unfortunately there is no quote by Metalenz.”
Metalenz is a fabless semiconductor optics company on a mission to revolutionize optical sensing with metasurface technology.
“Working with M Ventures has provided us with unparalleled access to world-class life science experts both within Merck KGaA, Darmstadt, Germany KGaA and beyond.”
LabGenius Therapeutics ("LabGenius") is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies.
https://labgeniustx.com/
“With M Ventures as an investor, we have gained access to a powerful network of senior life science leaders, opening doors to top-tier hires, investors, and potential partners.”
LabGenius Therapeutics ("LabGenius") is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies.
“M Ventures has proven to be a true thought partner with a real focus on driving long-term value creation. The M Ventures team are both generous with their time and have consistently provided high-value strategic insights.”
LabGenius Therapeutics ("LabGenius") is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies.
“MV investment brings smart capital that truly understands the semiconductor and deep-tech landscape. Beyond funding, they bring a team that is highly committed, engaged, and supportive of their portfolio companies.“
Quintessent enables the next generation of optical interconnects with highest bandwidth
“The team’s deep understanding of the biopharmaceutical sector and extensive network has been invaluable. M Ventures were instrumental in bringing together our Series A investment consortium. From our first interaction with Merck KGaA, Darmstadt, Germany, winning the 2018 ‘Displaying Futures Award’, the relationship has been tremendously supportive.”
Abselion is an analytical tool developer commercialising a hardware system and consumable sensor chip component that together enable the Simple, rapid, low cost acquisition of ELISA data.
“The team’s deep understanding of the biopharmaceutical sector and extensive network has been invaluable.”
Abselion is an analytical tool developer commercialising a hardware system and consumable sensor chip component that together enable the Simple, rapid, low cost acquisition of ELISA data.
Latest News
-
Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy
-
ReproNovo Announces First Participant Included in U.S. Phase 2 Trial of RPN-001 for Male Infertility
-
NTT DATA and Corvic AI Partner on GenAI Value Drivers
-
M Ventures Announces Key Leadership Changes in Technology Investment Team
-
ReproNovo raises $65 Million Series A Financing to advance phase 2 clinical trials of novel therapies in reproductive medicine and Womens's Health
-
Enara Bio Strengthens Senior Leadership with Key Executive and Board Appointments Alongside Acceleration of Multiple T-Cell Engager Programs
